Bosutinib therapy resulting in severe deterioration of pre-existing pulmonary arterial hypertension

European Respiratory Journal

Volumn 48, Issue 5, 2016, Pages 1514-1516

  Hickey, Peter M ^a,b   Thompson, Alfred A R ^a,b   Charalampopoulos, Athanasios ^b   Elliot, Charles A ^b   Hamilton, Neil ^b   Kiely, David G ^b   Lawrie, Allan ^a   Sabroe, Ian ^a,b   Condliffe, Robin ^b  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b ROYAL HALLAMSHIRE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMBRISENTAN; BOSUTINIB; DASATINIB; DIURETIC AGENT; ILOPROST; IMATINIB; NILOTINIB; PONATINIB; SILDENAFIL; TADALAFIL; ANILINE DERIVATIVE; NITRILE; QUINOLINE DERIVATIVE;

ACUTE HEART FAILURE; ADULT; CARDIOVASCULAR MAGNETIC RESONANCE; CASE REPORT; CHRONIC MYELOID LEUKEMIA; DETERIORATION; DISEASE ASSOCIATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; HEART CATHETERIZATION; HEART INDEX; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RIGHT ATRIUM PRESSURE; HEART RIGHT VENTRICLE EJECTION FRACTION; HEART RIGHT VENTRICLE ENDDIASTOLIC VOLUME; HEART RIGHT VENTRICLE FAILURE; HOSPITAL ADMISSION; HUMAN; LETTER; LUNG ARTERY PRESSURE; LUNG VASCULAR RESISTANCE; MALE; OXYGEN SATURATION; PERIPHERAL EDEMA; PLEURA EFFUSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; TREATMENT RESPONSE; WALKING;

ANILINE COMPOUNDS; FAMILIAL PRIMARY PULMONARY HYPERTENSION; HUMANS; HYPERTENSION, PULMONARY; NITRILES; QUINOLINES;

EID: 84994291424     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/13993003.01004-2016     Document Type: Letter

References (9)

1. Quilot FM, Georges M, Favrolt N, et al. Pulmonary hypertension associated with ponatinib therapy. Eur Respir J 2016; 47: 676-679.
2. Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res 2006; 66: 11314-11322.
3. Electronic Medicines Compendium. Summary of product characteristics: bosulif 100 mg and 500 mg tablets. http://www.medicines.org.uk/emc/medicine/27795 Date last accessed: April 25, 2016. Date last updated: July 8, 2016.
4. ClinicalTrials.gov. Efficacy, safety, tolerability and pharmacokinetics (PK) of nilotinib (AMN107) in pulmonary arterial hypertension (PAH). https://clinicaltrials.gov/ct2/show/record/NCT01179737?sect=X30156 Date last accessed: May 17, 2016. Date last updated: April 14, 2014.
5. Shah NP, Wallis N, Farber HW, et al. Clinical features of pulmonary arterial hypertension in patients receiving dasatinib. Am J Hematol 2015; 90: 1060-1064.
6. Montani D, Bergot E, Günther S, et al. Pulmonary arterial hypertension in patients treated by dasatinib. Circulation 2012; 125: 2128-2137.
7. Nagaraj C, Tang B, Bálint Z, et al. Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J 2013; 41: 85-95.
8. Pullamsetti SS, Berghausen EM, Dabral S, et al. Role of Src tyrosine kinases in experimental pulmonary hypertension. Arterioscler Thromb Vasc Biol 2012; 32: 1354-1365.
9. Prewitt AR, Ghose S, Frump AL, et al. Heterozygous null bone morphogenetic protein receptor type 2 mutations promote SRC kinase-dependent caveolar trafficking defects and endothelial dysfunction in pulmonary arterial hypertension. J Biol Chem 2015; 290: 960-971.